modelOzanimod

Diagram of Ozanimod

Extends from Pharmacolibrary.Drugs.ATC.L.L04AE02.

Information

name:Ozanimod
ATC code:L04AE02
route:oral
compartments:2
dosage:1mg
volume of distribution:5590L
clearance:230L/h
other parameters in model implementation

Ozanimod is an oral sphingosine 1-phosphate receptor modulator used primarily for the treatment of relapsing forms of multiple sclerosis (MS) and moderately to severely active ulcerative colitis. It reduces the migration of lymphocytes into the central nervous system, decreasing inflammatory damage. Ozanimod is a currently approved and marketed drug.

Pharmacokinetics

Pharmacokinetics model parameters reported after oral administration of single or multiple doses (1 mg) in healthy adult subjects.

References

  1. Selmaj, KW, et al., & Kappos, L (2021). Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple sclerosis and related disorders 51 102844–None. DOI:10.1016/j.msard.2021.102844 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33892317

  2. Briggs, E, et al., & Tran, JQ (2021). Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects. CPT: pharmacometrics & systems pharmacology 10(2) 119–126. DOI:10.1002/psp4.12580 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33314790

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)